Fujirebio Europe has announced the release of the Lumipulse G hs Troponin I assay for use in the diagnosis of Acute Myocardial Infarction (AMI). In addition, the company also launches its Lumipulse G Myoglobin assay, both assays providing precise and sensitive results in 35 minutes.
Press releases and announcements
Fujirebio Europe today announced the release of the Lumipulse G β-Amyloid 1-42 assay for its fully automated LUMIPULSE immunoassay systems. This CE-marked CLEIA (chemiluminescent enzyme immunoassay) kit allows the quantitative measurement of β-amyloid1-42 in human cerebrospinal fluid within just 30 minutes. The Lumipulse G β-Amyloid 1-42 assay is based upon Fujirebio’s well established, pioneering ELISA-based INNOTEST® assay (the first neurodegeneration testing kit launched in 1995) and the know-how of Fujirebio in robust and automated CLEIA testing since the first LUMIPULSE instrument was released in 1992.
Since January 2nd 2017 Fujirebio Diagnostics AB (headquarters in Sweden) and Fujirebio Europe NV (headquarters in Belgium) share the same website, www.fujirebio-europe.com.
Fujirebio Europe today announced the release of Lumipulse G HMW Adiponectin, a biomarker useful in the diagnosis of insulin resistance in obesity and of metabolic syndrome, available on the fully automated LUMIPULSE G series of instruments.
Fujirebio Europe today announced the release of Lumipulse G whole PTH, a 3rd generation assay that is highly useful in the diagnostic of primary hyperparathyroidism, hypoparathyroidism as well as secondary hyperparathyroidism, mainly in nephrology. The Lumipulse G whole PTH is calibrated against the international standard NIBSC WHO 95/646.
Gent, Belgium: July 5th 2016 - Fujirebio Europe has launched a communication campaign under the title "A few drops of insight can lead to an ocean of understanding" intended to help doctors, nurses and healthcare workers explain to patients and their families the advantages of an early diagnosis of Alzheimer's Disease through CSF (Cerebrospinal fluid) testing.
Fujirebio Europe today announced the release of Lumipulse G BNP, its brain-type natriuretic peptide (BNP) assay for the fully automated LUMIPULSE G series. The assay allows for quantitative measurement of human BNP in human EDTA plasma in an in vitro diagnostics setting.
Fujirebio Europe today announced the release of the Lumipulse G Mesothelin assay for its fully automated LUMIPULSE G1200 immunoassay system. This CE-marked CLEIA (chemiluminescent enzyme immunoassay) kit allows for quantitative determination of Soluble Mesothelin Related Peptides (SMRP) in human serum or plasma within just 30 minutes.
We are pleased to announce that our Lumipulse G 25-OH Vitamin D assay has recently been approved by the Vitamin D Standardization Certification Program. This program assesses the assay performance (bias and imprecision) of the lab or assay manufacturer throughout 1 year. Certification means the assay is standardized towards the reference measurement procedure. To know the performance of our assay in routine samples, including special clinical groups,
Fujirebio announces the availability of its fully automated chemiluminescent enzyme immunoassay (CLEIA) systems, the LUMIPULSE G1200 and the LUMIPULSE G600II, in the United Arab Emirates through the distribution partner Al Hayat. The LUMIPULSE G series will also be available in the Nordic Countries through a collaboration with Addtech Group.